Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841583 | 0.84 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL726305 | 0.84 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020812 | 0.84 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020665 | 0.84 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020671 | 0.84 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| Faxeladol SCHEMBL149508 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2B | |
| Faxeladol SCHEMBL616828 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2B | |
| Faxeladol SCHEMBL354208 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2B | |
| SCHEMBL1841310 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| Faxeladol SCHEMBL149507 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011147576-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 1-AMINOMETHYL-2-PHENYL-CYCLOHEXANE COMPOUNDS | Grünenthal GmbH (DE) | 2011-12-01 | — | — | WO | disclosed |